Summary

This article presents a poster with results of a Phase 3 trial to evaluate the efficacy and tolerability of levomilnacipran extended-release (ER) dose in adult patients with major depressive disorder [APA 2014 (poster NR6-087); NCT00969709]. The results of the study indicated that higher doses of levomilnacipran ER may benefit some patients, including those with moderate to severe depression.